A research study titled, “Orthobiologics Market by Product, Application, and End User - Global Industry Analysis and Forecast to 2025” published by Crystal Market Research, states that the orthobiologics market is projected to be around $10billion by 2025.
Orthobiologics helps to heal injured muscles, fractures, tendons and ligaments more quickly. These are made up of naturally occurring body substances such as autologous conditioned serum, autologous blood, bone grafts, stem cells, platelet rich plasma, and growth factors. Therefore, these are commercially available for orthopedic applications such as joint reconstruction, spinal fusion, and sports related injuries.
Rise in number of orthopedic surgeries, rapidly aging population, increasing adoption of advanced products, and growing demand for minimal invasive procedures are set to drive the global market for orthobiologics. As per the report published by American Academy of Orthopedic Surgeons, in U.S., around 500,000 bone grafting surgeries are performed every year. Of these, almost half of the surgeries are related to spinal fusion. These large number of procedures lead to rise in demand for musculoskeletal tissue donation and a shortage of cadaver material.
Additionally, increased availability of products with high osteoinductive and osteoconductive properties will further contribute to the market growth. An osteoinductive protein provides biophysical stimulation which helps to repair and regenerate bone fractures. Moreover, the high demand for orthobiologics in orthopedic industry coupled with rise in adoption of orthobiologics in different orthopedic applications such as joint reconstruction, trauma, craniomaxillofacial, and spinal fusion is set to boost the market growth.
Viscosupplementation segment dominated the global market in 2016 as they result in better knee movement, fewer side-effect, effective pain reduction and are less invasive in nature. As demand for minimally invasive procedures is on the rise, high adoption of viscosupplementation by the patient community is expected to contribute to the market growth during the forecast period. Synthetic bone substitutes along with stem cell based products are expected to exhibit lucrative growth during the forecast period owing to reduced cost, reduced risk of disease infection and quick recovery.
Spinal fusion segment dominated the overall market in 2016. This dominance can be attributed to large scale adoption of autografts and bone morphogenetic proteins in spinal fusion surgeries. The procedure provides high bone stability along with rapid healing of the bones which results in effective improvement in case of long-term spine related disorders. Moreover, the availability of favorable reimbursement policies for fusion enhancement products is expected to contribute to the growth of spinal fusion segmentduring the forecast period.
Hospitals segment dominated the global market in 2016 owing to the large scale adoption of orthobiologics products for spinal and reconstructive surgeries. Furthermore, factors such as large procedure volumes, frequent readmissions and high patient turnaround are anticipated to further drive the growth of hospitals market during the forecast period.
U.S. held the major share of North American orthobiologics market in 2016 owing to the presence of numerous market players in the country. With the availability of advanced healthcare facilities and research capabilities, the market is supposed to witness impressive growth over the forecast period. Emerging economies such as China and India in the Asia-Pacific region are expected to register highest growth during the forecast period. This rapid growth can be attributed to factors such as rising geriatric population, untapped medical needs in these countries along with increasing medical tourism.
Development of novel products related to bone healing has changed the field of orthopedic treatment. Therefore, major players are highly focused on developing and commercializing technologically advanced products. For instance, in September 2015, Wright Medical Group Inc. obtained premarket approval for its Augment bone graft from FDA. This graft can be used in ankle or hind foot fusion procedures. Similarly, in November 2015, CeraPedics, an orthobiologics company, obtained premarket approval (PMA) application for its “i-FACTOR Peptide Enhanced Bone Graft”. This graft can be used for the treatment of degenerative cervical disc related disorders. Thus, introduction of technologically advanced products is set to propel the market growth.
Some of the key players in orthobiologics market are, Bioventus LLC., Smith & Nephew PLC, RTI Surgical, Inc., Bone Biologics Corporation, CollPlant Ltd, Musculoskeletal Transplant Foundation, AlloSource, Seikagaku Corporation, Kuros Biosciences AG, DePuySynthes (A subsidiary of Johnson & Johnson Services, Inc.), ISTO Technologies, Inc., OsteoMed, Stryker Corporation, Arthrex, Inc., Osiris Therapeutics, Inc., Globus Medical Inc., Medtronic plc, NuVasive, Inc. and Wright Medical Group N.V.
Browse full research report with TOC on “Orthobiologics Market by Product, Application, and End User - Global Industry Analysis and Forecast to 2025” at:
https://www.crystalmarketresearch.com/report/orthobiologics-market
Key Findings of the Research Study:
The orthobiologics market is expected to be around $10 billion by 2027. The market is primarily driven by factors such as increasing number of orthopedic surgical procedures performed worldwide due to rising incidence of accidents and sports related injuries.